William Blair Has Optimistic Outlook of KZR FY2024 Earnings

Kezar Life Sciences, Inc. (NASDAQ:KZR) – Investment analysts at William Blair upped their FY2024 EPS estimates for Kezar Life Sciences in a note issued to investors on Wednesday, November 13th. William Blair analyst M. Phipps now expects that the company will earn ($2.06) per share for the year, up from their prior forecast of ($12.50). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($6.47) per share. William Blair also issued estimates for Kezar Life Sciences’ Q4 2024 earnings at ($2.81) EPS, Q1 2025 earnings at ($2.73) EPS, Q2 2025 earnings at ($2.75) EPS, Q3 2025 earnings at ($2.78) EPS, Q4 2025 earnings at ($2.80) EPS, FY2025 earnings at ($11.06) EPS, FY2026 earnings at ($11.86) EPS and FY2027 earnings at ($12.84) EPS.

Several other analysts have also recently issued reports on the company. HC Wainwright restated a “neutral” rating on shares of Kezar Life Sciences in a report on Monday, October 14th. Wells Fargo & Company dropped their price objective on shares of Kezar Life Sciences from $20.00 to $11.00 and set an “equal weight” rating for the company in a report on Thursday, November 14th.

Kezar Life Sciences Price Performance

NASDAQ:KZR opened at $7.39 on Monday. Kezar Life Sciences has a one year low of $5.20 and a one year high of $11.35. The stock has a market cap of $53.92 million, a PE ratio of -0.56 and a beta of 0.22. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.58 and a current ratio of 7.65. The stock has a 50 day moving average price of $7.24 and a 200 day moving average price of $6.81.

Kezar Life Sciences (NASDAQ:KZR) last released its earnings results on Tuesday, November 12th. The company reported ($2.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.03) by $0.25.

Institutional Investors Weigh In On Kezar Life Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KZR. Vanguard Group Inc. raised its stake in shares of Kezar Life Sciences by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 3,094,224 shares of the company’s stock valued at $2,790,000 after acquiring an additional 30,740 shares during the period. Acadian Asset Management LLC increased its holdings in Kezar Life Sciences by 3.6% in the 2nd quarter. Acadian Asset Management LLC now owns 1,855,194 shares of the company’s stock valued at $1,112,000 after purchasing an additional 64,356 shares during the last quarter. Affinity Asset Advisors LLC purchased a new stake in Kezar Life Sciences in the first quarter valued at approximately $1,588,000. Stonepine Capital Management LLC lifted its stake in Kezar Life Sciences by 42.0% during the third quarter. Stonepine Capital Management LLC now owns 1,491,305 shares of the company’s stock worth $1,153,000 after purchasing an additional 440,853 shares in the last quarter. Finally, Ikarian Capital LLC boosted its position in shares of Kezar Life Sciences by 23.0% during the third quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock worth $827,000 after buying an additional 200,000 shares during the period. Hedge funds and other institutional investors own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.